Accelerating Dementia Pathway Technologies (ADEPT)

Cognetivity is a pre-revenue, UK-based SME focusing on AI-enabled digital technologies. Cognetivity aim to reduce the time and costs for the diagnosis of Dementia, Alzheimer's and Mild-Cognitive Impairment using the Integrated Cognitive Assessment (ICA) software technology. This uses a novel artificial intelligence-based approach to conduct a simple 5-minute test on an Apple iPad that is not dependent on education or culture and, unlike current tests, cannot be learned.There are an estimated 850,000 people with dementia in the UK, with numbers set to rise to over 1 million by 2025, 1 in 6 people over the age of 80 have dementia, and more than 25,000 people from BAME communities in the UK are affected (Alzheimer's Society/SCIE, 2018). The average diagnosis lead time in the UK can range from 6 weeks to a year for specialist consultations (Alzheimer's Society, 2014).In line with the Dementia Challenge 2020, addressing the diagnosis rate, accuracy and usability are urgent needs to tackle an ever-growing issue with an ageing population.This project has three objectives, to:1. deliver real-world evidence study on the practice and economic case for the adoption of ICA in memory clinics for the assessment of cognitive impairment associated with dementia, Alzheimer's Disease and similar diseases,2. define policy and pathway changes in primary care for screening and referral of patients3. development project for the technical integrations needed to embed the new digital technology seamlessly to transform care pathways.The study will aim to enrol 600 participants at 5 memory clinics from ca.70 GP surgeries, using the existing dementia pathways and ICA over a period of 12 months.This project will develop the capability to integrate the ICA into existing healthcare information systems. The project will also assess the practical and economic benefits of the new digital technology, in terms of NHS time and resource saving, and benefits for patients. Successful completion will underpin future sales of ICA into primary care and secondary care settings within the UK and internationally, as exports, both for diagnosis and progression monitoring.Awaiting Public Project Summary